Eli Lilly to Acquire Pre-Clinical Biotech CrossBridge for Up to $300M

The deal bolsters Lilly's cancer drug pipeline with CrossBridge's antibody-drug conjugate technology.

Apr. 14, 2026 at 2:53pm

Got story updates? Submit your updates here. ›

A high-end, photorealistic studio still-life photograph featuring a polished glass vial filled with a glowing, translucent liquid, symbolizing a new cancer drug candidate. The vial is placed on a clean, monochromatic seamless background, using sharp, dramatic studio lighting and deep shadows to represent the abstract scientific innovation behind the acquisition.Lilly's acquisition of CrossBridge's antibody-drug conjugate technology signals the pharmaceutical giant's strategic focus on expanding its cancer drug pipeline.Indianapolis Today

Pharmaceutical giant Eli Lilly has agreed to acquire pre-clinical biotech company CrossBridge Bio for up to $300 million. The deal includes an undisclosed upfront payment and potential milestone payments. CrossBridge is developing dual-payload antibody-drug conjugates (ADCs), with its lead candidate expected to enter clinical trials later this year. The acquisition strengthens Lilly's cancer drug pipeline, as the company recently received breakthrough therapy designation from the FDA for its own ADC candidate.

Why it matters

The acquisition of CrossBridge aligns with Lilly's strategic focus on expanding its oncology portfolio through external innovation. ADCs are a rapidly growing class of targeted cancer therapies, and Lilly's investment in domestic ADC manufacturing capacity signals its commitment to this treatment approach. The deal also highlights the value of pre-clinical biotechs with promising early-stage drug candidates.

The details

Under the terms of the agreement, Lilly will pay an undisclosed upfront sum to acquire CrossBridge, along with potential milestone payments. CrossBridge is developing dual-payload ADCs, which pair antibodies with toxic agents to help deliver chemotherapy directly to tumor cells. The company's lead ADC candidate is expected to enter clinical trials later this year. Lilly recently received breakthrough therapy designation from the FDA for its own ADC drug candidate, sofetabart mipitecan, for certain ovarian cancer patients. The Indianapolis-based pharmaceutical company also announced plans last year to build a $5 billion manufacturing plant in Virginia to increase its domestic production of ADCs.

  • Eli Lilly agreed to acquire CrossBridge Bio on April 14, 2026.
  • Lilly's lead ADC candidate, sofetabart mipitecan, received FDA breakthrough therapy designation in January 2026.
  • Lilly announced plans in 2025 to build a $5 billion ADC manufacturing plant in Virginia.

The players

Eli Lilly

A global pharmaceutical company headquartered in Indianapolis, Indiana, known for its innovative drug development and manufacturing capabilities.

CrossBridge Bio

A pre-clinical stage biotechnology company based in Houston, Texas, that is developing dual-payload antibody-drug conjugates for cancer treatment.

Got photos? Submit your photos here. ›

What’s next

Lilly expects CrossBridge's lead ADC candidate to enter clinical trials later this year, marking a key milestone in the integration of the two companies' drug development pipelines.

The takeaway

Lilly's acquisition of CrossBridge demonstrates the pharmaceutical giant's commitment to bolstering its cancer drug portfolio through strategic investments in promising pre-clinical biotechnology companies. The deal highlights the growing importance of antibody-drug conjugates as a targeted cancer therapy approach, and Lilly's parallel investments in domestic ADC manufacturing capacity signal its long-term confidence in this treatment modality.